Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Multiple Sclerosis Disease Activity and Disability Following Discontinuation of Natalizumab for PregnancyJAMA Netw Open 2022 Jan 04;5(1)e2144750, K Hellwig, M Tokic, S Thiel, N Esters, C Spicher, N Timmesfeld, AI Ciplea, R Gold, A Langer-Gould
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.